Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with bisphosphonates alone or in combination with pitavastatin over an 18-month follow-up after more than 4 years of treatment with bisphosphonates by Masakazu Nagashima et al.
RESEARCH ARTICLE Open Access
Osteogenesis and osteoclast inhibition in
rheumatoid arthritis patients treated with
bisphosphonates alone or in combination with
pitavastatin over an 18-month follow-up after more
than 4 years of treatment with bisphosphonates
Masakazu Nagashima1*, Hiroshi Takahashi1, Kenichi Shimane1, Yuichi Nagase1 and Koichi Wauke2
Abstract
Introduction: To investigate the effects of bisphosphonates (Bis) (etidronate, alendronate, and risedronate), alone
and in combination with statin, on the BMD (bone mineral density) and bone metabolism of rheumatoid arthritis
(RA) patients.
Methods: Seventy-seven RA patients who had been receiving prednisolone (PSL) and Bis for over 4 years were
divided into two groups: Bis and Bis + statin (n = 42 and 35; average age, 66.4 and 65.3 years; average disease
duration, 24.9 and 20.8 years; average PSL dose, 2.4 and 2.7 mg, respectively). Serum levels of NTX (N-terminal
telopeptide of type I collagen), TRACP-5b (tartrate-resistant acid phosphate-5b), PICP (C-terminal propeptide of type
I procollagen), and RANKL (receptor activator of NF-B ligand) were measured over an 18-month period of
treatment and follow-up. The BMD levels of the two groups at the radius, lumbar spine, and femoral neck were
compared using DXA (dual-energy x-ray absorptiometry).
Results: A significant increase was only observed in the BMD of the lumbar spine at 18-months, but the BMDs of
the radius and femoral neck decreased during the follow-up period in the Bis group. Meanwhile, a significant
increase was observed in the BMD of the lumbar spine in the Bis + statin group during administration and the
BMDs of the radius and femoral neck stayed at baseline. Among the markers of bone metabolism, serum NTX was
up-regulated after 6 months in the Bis + statin group. Serum TRACP-5b was significantly increased during the
follow-up period in the Bis + statin group, but only at 18 months in the Bis group. Serum PICP recovered to base
line in the Bis + statin group, whereas that in the Bis group did not observably recover during the post-
administration follow-up, but rather decreased.
Conclusion: Our findings suggest that both bone resorption and bone formation were inhibited by long-term
administration of Bis alone, whereas combination therapy with Bis + statin may be associated with a less marked
inhibition of bone metabolism. Cardiovascular disease is highly prevalent in RA patients and some patients are
prescribed statins and bisphosphonate. Bis + statin may confer more benefit to the bone metabolism of these
patients compared to Bis alone.
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Introduction
Loss of bone mass is frequently seen in patients with
rheumatoid arthritis (RA). The main causes of osteoporo-
sis in patients with RA are reportedly steroid therapy,
postmenopausal changes in hormone balance (postmeno-
pausal osteoporosis), and disuse bone atrophy associated
with periarticular impairment [1,2]. Conversely, bone and
cartilage damage in RA results from an imbalance
between synthesis and degradation caused by cellular and
cytokine-mediated inflammation. Growing evidence
demonstrates that the increased bone resorption in bone
diseases such as osteoporosis and RA is linked to the
facilitation of osteoclast differentiation and activation by
inflammatory cytokines of TNF-a and IL-1 [3-5]. Osteo-
protegerin (OPG), a secreted soluble decoy receptor with
homology to the members of the TNF receptor family,
binds to the receptor activator of NF-B ligand (RANKL)
and blocks interactions with the receptor activator of
NF-B [6,7]. An imbalance in this system may play a part
in the skeletal complications of RA [8].
Bisphosphonates (Bis), a class of agents taken up by
osteoclasts and macrophages to inhibit the activity of
inflammatory cytokines, are thought to inhibit the
inflammation induced by these cells. Etidronate, a non-
amino Bis, is reportedly effective in relieving pain in
patients suffering from steroid-induced osteoporosis,
postmenopausal osteoporosis, and osteoarthritis. Like-
wise, the amino-bisphosphonate risedronate is reportedly
effective as a treatment for decreased bone density and
vertebral fracture in patients on corticosteroid therapy
[9,10]. Our group previously examined whether intermit-
tent cyclical etidronate inhibits bone resorption or
inflammatory changes over two study periods of 1.5 years
and 3 years, in osteoporotic patients with RA [11,12].
Etidronate also inhibited the production of mediators
related to inflammation, pain, and angiogenesis, namely
IL-6, prostaglandin E2, substance P, and vascular
endothelial growth factor, in synovial cells of arthritic
models [12].
Statins have recently been reported to stimulate bone
formation in vivo [13,14] as effectively as vitamin K2 (vit
K2), to stimulate osteoblastogenesis, and to inhibit osteo-
clastogenesis in human bone marrow cell culture [15], and
also to inhibit bone loss induced by prednisolone (PSL) in
rats [16]. Clinical trials by our group have clarified that Vit
K2 alone or in combination with Bis may inhibit osteoclast
induction by decreasing the levels of RANKL [17].
The present study examined the effects of Bis (etidro-
nate, alendronate and risedronate) alone and in combi-
nation therapy with statins on bone mineral density
(BMD) and on four markers of bone metabolism,
namely N-terminal telopeptide of type I collagen (NTX),
tartrate-resistant acid phosphate-5b (TRACP-5b),
C-terminal propeptide of type I procollagen (PICP) and
RANKL in patients with RA.
Materials and methods
The study subjects were 77 patients with RA who fulfilled
the diagnostic criteria of the American College of Rheu-
matology (ACR) [18] and had been receiving PSL and Bis
for over 4 years. They were divided into two groups: Bis
(n = 42) and Bis + statin (n = 35). The drugs adminis-
tered in the Bis group were 35 mg of alendronate (n = 31
patients), 400 mg of etidronate (n = 4 patients) and 17.5
mg of risedronate (n = 7 patients). The drugs adminis-
tered in the Bis + statin group were alendronate and 2
mg of pitavastatin (n = 26 patients), etidronate and pita-
vastatin (n = 5 patients), and risedronate and pitavastatin
(n = 4 patients). The patients diagnosed with hyperlipide-
mia also received pitavastatin, with their informed con-
sent. The patients were selected from the outpatient
clinic of our department in Tokyo Metropolitan Bokutoh
Hospital. A 400 mg dose of etidronate was administered
orally between meals for 2 weeks, and was then withheld
for the next 10 weeks. This 12-week period was defined
as one cycle of etidronate treatment, and the cycle was
repeated 6 times (72 weeks, 18 months).
The mean age ± SD of the patients was 66.4 ± 6.2 years
in the Bis group and 65.3 ± 6.8 years in the Bis + statin
group. The mean disease duration was 24.9 ± 10.6 years in
the Bis group and 20.8 ± 8.9 years in the Bis + statin
group. Adrenal corticosteroid in the form of 1-7 mg of
PSL was administered once daily to 30 patients in the Bis
group and 28 patients in the Bis + statin group (mean PSL
doses of 2.4 ± 2.0 mg and 2.7 ± 2.1 mg, respectively).
A 0.5 μg dose of vitamin D3 was administered once daily
to seven patients in the Bis group and three patients in the
Bis + statin group. Calcium was not administered to
patients in either group. Almost all of the patients received
disease-modifying anti-rheumatic drugs (DMARDs). The
most frequently used DMARDs were methotrexate (MTX)
and salazosulfapyridine, but eight patients (six Bis patients
and two Bis + statin patients) were prescribed biological
agents (TNF-a blockades). MTX was administered to
34 Bis and 25 Bis + statin patients, at mean MTX doses of
5.2 ± 3.2 mg (range 2 to 10 mg) and 4.1 ± 3.1 mg (range 2
to 10 mg), respectively. The duration of Bis treatment
exceeded 5 years in 27 Bis patients and in 22 Bis + statin
patients, averaging over 4.2 years and over 3.9 years,
respectively. There was no period of drug cessation before
the study was initiated. The PSL and MTX doses were not
increased, and no other medications were administered.
This study was approved by the Ethical Committee of
Tokyo Metropolitan Bokutoh Hospital. All patients gave
their informed consent. No significant differences between
the Bis and Bis + statin groups were observed in the
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background data or in the baseline data on serum bone
markers and BMD (Tables 1 and 2). During an 18-month
period of treatment and follow-up, the BMD of the radius,
lumbar spine (vertebra L3), and femoral neck were mea-
sured by dual-energy x-ray absorptiometry (DXA)
(QDR4500, Hologic Inc., Bedford, MA, USA). The follow-
ing markers were measured by ELISA and were compared
in the two groups: serum NTX and TRACP-5b as markers
of bone resorption (ELISA, Alere Medical, Tokyo, Japan;
DS Pharma Biomedical, Osaka, Japan), serum PICP as a
marker of osteogenesis (ELISA, Takara, Japan), and serum
levels of RANKL (ELISA, Biomedica, Vienna, Austria)
(Table 3).
All data are expressed as means ± SD. All background
data in the patients with RA were analyzed using Stu-
dent’s t-test. Percentage changes in all parameters
(BMD measured by DXA, NTX, TRACP-5b, PICP, and
RANKL) at 0, 6, 12, and 18 months in the Bis and Bis +
statin groups relative to the baseline measurements were
evaluated using the Wilcoxon signed ranks test, and dif-
ferences in percentage changes at 0, 6, 12, and 18
months between the Bis and Bis + statin groups were
evaluated using the Mann-Whitney U-test. A P-value
less than 0.05 was assumed to indicate a statistically sig-
nificant difference.
Results
Measurement of BMD by DXA
Background data on the patients with RA are shown in
Table 1. No significant differences in these parameters
were observed between the two groups. The percent
changes in BMD of the radius were -0.6% and -1.7% at
6 months after the start of treatment, -2.5% and 0.1% at
12 months and -2.5% and -0.6% at 18 months in the Bis
and Bis + statin groups respectively. Statistical analysis
of these two groups at 12 and 18 months showed signif-
icant decreases in the Bis group and increases at a sub-
significant level in the Bis + statin group (Figure 1).
The percent changes in BMD of the lumbar spine in
the Bis and Bis + statin groups were 0.7% and 2.3% at 6
months after the start of treatment, 1.2% and 2.4% at 12
months, and 3.3% and 3.5% at 18 months, respectively.
Statistical analysis of these two groups showed signifi-
cant increases at 6, 12, and 18 months in the Bis + sta-
tin group and a significant increase at 18 months in the
Bis group (Figure 2).
The percent changes in BMD of the femoral neck in
the Bis and Bis + statin groups were -1.3% and 0.4% at
6 months after the start of treatment, -1.2% and -1.6%
at 12 months, and -2.7% and -0.9% at 18 months,
respectively. Statistical analysis of these two groups over
Table 1 Background data for patients with rheumatoid arthritis (RA)
Bisphosphonate group
(n = 42)








59 > 3 8
60-69 24 17
70 < 13 10






> 4 years 29 22
1 to 4 years 13 13
Prednisolone, mg 2.4 ± 2.0 (0, 6.0) 2.8 ± 2.1 (0, 7.0) 0.355
+ 30 28
- 12 7
Methotrexate, mg 5.2 ± 3.2 (0, 10) 4.1 ± 3.1 (0, 10) 0.140
+ 34 25
- 8 10
Vitamin D3, μg 0.5 0.5
+ 7 3
- 35 32
Results are presented as mean ± SD (range) or number of patients. P-values are for comparisons between the two treatment groups.
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the follow-up period showed significant decreases in the
Bis group at 6 and 18 months, and no significant
decreases in the Bis + statin group (Figure 3).
These results demonstrated a significant increase in
BMD of the lumbar spine during the follow-up period in
the Bis + statin group. The BMD of the radius and femoral
neck decreased significantly during the follow-up period in
the Bis group, but not in the Bis + statin group.
Measurement of serum NTX, TRACP-5b, PICP and RANKL
as markers of bone resorption, formation, and
destruction
The percent changes in serum NTX in the Bis and Bis +
statin groups were -3.8% and -2.6% at 6 months after the
start of treatment, -7.2% and -0.3% at 12 months, and
-4.5% and 1.4% at 18 months, respectively (Figure 4).
Serum NTX at 12 months was significantly decreased in
the Bis group. The Bis + statin group exhibited no such
decrease at 12 months, but rather an up-regulation in the
level of serum NTX after 6 months during the follow-up
period. Namely, inhibition of bone resorption was gradu-
ally restricted after the start of Bis + statin treatment. In
addition to NTX, the percent changes in serum TRACP-
5b, a marker of bone resorption, were 3.2% and 10.9% at
6 months after the start of treatment, 4.9% and 12.5% at
12 months, and 20.8% and 20.7% at 18 months, respec-
tively, in the Bis and Bis + statin groups (Figure 5). Serum
TRACP-5b was significantly increased throughout the
whole follow-up period in the Bis + statin group, but only
at 18 months in the Bis group.
The percent changes in serum PICP in the Bis and Bis +
statin groups were 10.6% and 10.0% at 6 months after the
start of treatment, 3.7% and -2.9% at 12 months, and
-7.0% and -1.5% at 18 months, respectively (Figure 6).
A significant increase in serum PICP, a marker of bone
formation, was observed at 6 months in both groups.
Serum PICP gradually decreased after 6 months in the Bis
and Bis + statin group but gradually recovered to baseline
in the Bis + statin group. In contrast, serum PICP did not
observably recover, but rather decreased in the Bis group.
The serum RANKL levels tended to decrease during
the follow-up period in the Bis and Bis + statin groups.
The serum RANKL had decreased to below a detectable











Radius 0.35 ± 0.08 (0.12, 0.54) 0.33 ± 0.13 (0.11, 0.63) 0.547
Lumbar spine 0.82 ± 0.18 (0.50, 1.32) 0.82 ± 0.180 (0.51, 1.40) 0.974
Femoral neck 0.64 ± 0.09 (0.39, 0.81) 0.60 ± 0.13 (0.33, 0.79) 0.096
NTX, nmol BCE/l 16.3 ± 5.4 (9.7, 35.6) 15.8 ± 4.2 (9.3, 27.9) 0.690
TRACP-5b, μU/dl 357 ± 1287(131, 628) 350 ± 102 (174, 652) 0.820
PICP, ng/ml 612 ± 218 (384, 1490) 562 ± 205 (289, 1340) 0.315
RANKL, pmol/l 0.27 ± 0.36 (0.13, 1.92) 0.16 ± 0.11 (0.13, 0.63) 0.093
Results are presented as mean ± SD (range). NTX, N-terminal telopeptide of type I collagen; TRACP-5b, tartrate-resistant acid phosphate-5b; PICP, C-terminal
propeptide of type I procollagen; RANKL, receptor activator of NF-B ligand. P-values are for comparisons between the two treatment groups.
Table 3 Measurement methods
Measurement Measurement method
BMD DXA (QDR4500, Hologic Inc., Bedford. MA)
NTX
TRACP-5b
ELISA (Alere Medical, Japan)
ELISA (DS Pharma Biomedical, Japan)
PICP ELISA (Takara, Japan)
RANKL ELISA (Biomedica, Vienna, Austria)
BMD, bone mineral density; NTX, N-terminal telopeptide of type I collagen;
TRACP-5b, tartrate-resistant acid phosphate-5b; PICP, C-terminal propeptide of
type I procollagen; RANKL, receptor activator of NF-B ligand; DXA, dual-































Figure 1 Percentage changes in bone mineral density (BMD) of
the radius measured by dual-energy x-ray absorptiometry
(DXA) at 6, 12 and 18 months after the start of treatment in
the Bisphosphonate (Bis) and Bis + statin groups. Circles
represent the Bis group and triangles represent the Bis + statin
group. Significant decreases in BMD of the radius were observed at
12 and 18 months in the Bis group. In the Bis + statin group, a
significant decrease was only observed at 6 months, and after 6
months tended to increase at 12 and 18 months. *P < 0.05, **P <
0.01, for comparison to baseline for each group.
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level over more than 4 years of treatment with Bis (data
not shown).
Discussion
In this study we investigated the effects of Bis, alone or in
combination with statins, on bone resorption and bone
formation based on BMD and various bone markers in
patients with RA who had been receiving Bis for more
than 4 years. Alendronate prevents the inhibition of osteo-
clast formation, bone resorption, and kinase activation in
vitro via inhibition of metabolism from farnesyl dispho-
sphate to geranylgeranyl diphosphate in the mevalonate
pathway [19]. Hydroxymethylglutanyl-CoA (HMG-CoA)
reductase inhibitors such as lovastatin, pravastatin, and
simvastatin also block the conversion of HMG-CoA to
































Figure 2 Percentage changes in bone mineral density (BMD) of
the lumbar spine measured by dual-energy x-ray
absorptiometry (DXA) at 6, 12 and 18 months after the start of
treatment in the bisphosphonate (Bis) and Bis + statin groups.
Circles represent the Bis group and triangles represent the Bis +
statin group. Significant increases in BMD of the lumbar spine were
observed at 6, 12 and 18 months in the Bis + statin group, but in
the Bis group a significant increase was only observed at 18
months. *P < 0.05, **P < 0.01, ***P < 0.001, for comparison to
baseline for each group.
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Figure 3 Percentage changes in bone mineral density (BMD) of
the femoral neck measured by dual-energy x-ray
absorptiometry (DXA) at 6, 12 and 18 months after the start of
treatment in the bisphosphonate (Bis) and Bis + statin groups.
Circles represent the Bis group and triangles represent the Bis +
statin group. Significant decreases in BMD of the femoral neck were
observed at 6 and 18 months in the Bis group, but in the Bis +
statin group a significant decrease in BMD was not observed during
the follow-up period. *P < 0.05, **P < 0.01, for comparison to



























Figure 4 Percentage changes in serum N-terminal telopeptide
of type I collagen (NTX) at 6, 12 and 18 months after the start
of treatment in the bisphosphonate (Bis) and Bis + statin
groups. Circles represent the Bis group and triangles represent the
Bis + statin group. A significant decrease in serum NTX was
observed at 12 months in the Bis group, but in the Bis + statin
group, serum NTX was up-regulated during the follow-up period
except at 6 months. *P < 0.05, **P < 0.01, for comparison to



























Figure 5 Percentage changes in serum tartrate-resistant acid
phosphate-5b (TRACP-5b) at 6, 12 and 18 months after the
start of treatment in the bisphosphonate (Bis) and Bis + statin
groups. Circles represent the Bis group and triangles represent the
Bis + statin group. Significant increases in serum TRACP-5b were
observed at 6, 12 and 18 months in the Bis + statin group, but in
the Bis group a significant increase was only observed at 18
months. *P < 0.05, *P < 0.01, ***P < 0.001, for comparison to
baseline for each group.
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geranylgeranyl-PP. Meanwhile, amino-bisphosphonates
and HMG-CoA reductase inhibitors have been shown to
increase macrophage (osteoclast-like cell) apoptosis
[20,21]. Statins and Bis inhibit different enzymes within
the same pathway. As such, we can expect statins and Bis
to confer similar effects on osteoclasts and macrophages.
HMG-CoA reductase inhibitors are also known to
increase new bone formation from osteoblasts and to
accelerate the promoter activity of bone morphorogic
protein-2 (BMP-2), a member of the BMP family [13].
Sugiyama et al. reported that simvastatin, but not pravas-
tatin, induced BMP-2 in human osteosarcoma cells [22].
The statin-mediated activation of BMP-2 promoter was
completely inhibited by the downstream metabolite of
HMG-CoA reductase, mevalonate, which meant that the
activation was a result of the inhibition of the enzyme. In
both prospective and retrospective studies of the same
patients, BMD of the lumbar spine in patients adminis-
tered fluvastatin was significantly increased compared
with administration of pravastatin at 6 and 12 months
after the start of the treatment [23]. In a similar study of
female patients, HMG-CoA reductase inhibitors signifi-
cantly increased BMD of the femoral neck after 15
months [24].
In our comparison between the Bis group and Bis + sta-
tin groups, the Bis group had a small increase in BMD at
the lumbar spine, versus significant decreases in BMD at
the radius and femoral neck during the follow-up period.
In the Bis + statin group, the BMD of the lumbar spine
significantly increased after 6 months of follow-up, while
the BMD of the radius and femoral neck did not decrease
significantly. Compared with subjects administered Bis
alone, the subjects receiving combination therapy had a
significant increase in BMD at the lumbar spine after the
start of treatment, while the BMD of the radius and
femoral neck stayed at baseline levels.
Several studies [25-27] have documented reductions in
NTX and increased BMD in postmenopausal osteoporo-
tic women administered bisphosphonates. The produc-
tion of NTX, a marker of bone resorption, decreased
during the follow-up period in the Bis group while
remaining unchanged following commencement of sta-
tin treatment in the Bis + statin group. These results
indicate that bone resorption was continuously inhibited
in the Bis group but was not inhibited in the Bis + statin
group.
Serum TRACP-5b, a marker of bone resorption,
increased during the follow-up period in both of our
groups and significantly increased after the start of statin
treatment in the Bis + statin group. Serum TRACP-5b
and TRACP protein have been found to increase signifi-
cantly in RA and conditions related to increased bone
resorption [28]. The increased total TRACP-5 protein in
RA was not derived from the osteoclasts, but may have
been a secreted product of inflammatory macrophages
and dendritic cells [29].
In our results, serum RANKL remained below detect-
able levels in our patients who received Bis over a long
period, hence osteoclast differentiation via the RANK/
RANKL system may have been depressed. The increase
of TRACP-5b may thus have been linked to osteoclast
differentiation or activation via TNF-aor IL-1, and
macrophages or dendritic cells. TRACP-5b increased
after the start of treatment in both groups, whereas NTX
increased after 6 months only in the Bis + statin group.
These results show that statins may depress the produc-
tion of NTX rather than the production of TRACP-5b.
Janckila et al. found no significant correlation between
TRACP-5b and serum bone alkaline phosphatase (BAP)
or NTX [30] in RA and observed that serum TRACP-5b
decreased less in response to clodronate than in response
to urinary NTX [31].
Patients with RA experience systemic osteoporosis and
produce various inflammatory cytokines that accelerate
bone resorption in joints, and high concentrations of solu-
ble RANKL are detected in their synovial fluid [32]. Serum
RANKL was already quite low at the start of treatment in
both of our groups, and it decreased further throughout
the follow-up period. Some studies have documented that
Bis alone or in combination therapy reduces RANKL
[17,33,34]. We have already reported that vit K2 alone or
Bis + vit K2 reduces RANKL to below the detectable level
at 6 months after the start of treatment [17].
Our measurement of the bone formation marker serum
PICP, showed a temporal increase in both groups at
6 months. At 12 months the increase was not maintained

























Figure 6 Percentage changes in serum C- terminal propeptide
of type I procollagen (PICP) at 6, 12 and 18 months after the
start of treatment in the bisphosphonate (Bis) and Bis + statin
groups. A significant increase in serum PICP was observed at 6
months in the Bis and Bis + statin group. On the other hand, in the
Bis + statin group serum PICP tends to increase after 12 months.
*P < 0.05, **P < 0.01, for comparison to baseline for each group.
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returned to baseline in the Bis + statin groups. When
Mostaza et al. [35] administered pravastatin to hypercho-
lesterolemic postmenopausal women, the agent increased
PINP, a marker of bone formation, without affecting
bone resorption. When alendronate was administered
alone and in combination with parathyroid hormone
(PTH), a marked increase of bone formation was
observed in the PTH alone group, but not in the combi-
nation group, and bone resorption decreased in both
groups [36]. These results suggest that the concurrent
use of alendronate may reduce the anabolic effects of
PTH.
Bis + statin appeared to block the inhibition of bone
resorption by up-regulating the levels of NTX and
TRCP-5b, whereas the level of RANKL was inhibited in
both groups. In our measurement of BMD in the Bis +
statin subjects, BMD of the radius and femoral neck
stayed at baseline levels despite temporal decreases,
while BMD of the lumbar spine increased significantly.
Conclusions
Our findings suggest that both bone resorption and bone
formation were inhibited by long-term administration of
Bis alone, whereas combination therapy with Bis + statin
may be associated with a less marked inhibition of bone
metabolism. We would like to recommend a combination
therapy of bisphosphonate with statin or vit K2, to pro-
mote bone formation for the treatment or prevention of
osteoporosis in RA patients.
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